Effects of Root Extract Ashwagandha (KSM-66) on Perception of Recovery and Muscle Strength in Adolescents Aged 11 to 19 Engaged in Grassroots Football
Effects of KSM-66 Ashwagandha (Withania Somnifera) Root Extract Supplementation on Perception of Recovery and Muscle Strength in Adolescents in Grassroots Football: A Randomised, Double-Blind, Placebo-Controlled Trial
This study will test whether six weeks of ashwagandha (KSM-66 root extract), helps teenage footballers recover and improve strength. Very little research has looked at young people aged 11 to 19, despite increased usage in this cohort.
About 50 to 60 male and female players from grassroots clubs in Sussex, Surrey and Greater London will be randomly assigned to take a daily capsule of either 450 mg ashwagandha or a placebo in an unblinded fashion. Before and after the six weeks, players will do tests at their usual training site: saliva samples to measure the cortisol, grip strength, a 1 km time trial, and short questionnaires on recovery, sleep, stress and soreness.
The results will show whether ashwagandha changes stress, strength, performance and perceived recovery over six weeks.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
This randomised, double-blind, placebo-controlled trial will test whether KSM-66 ashwagandha (Withania somnifera) root extract alters physiological stress, neuromuscular performance and perceived recovery in adolescent footballers. In adults, standardised root extract has been associated with improved strength, recovery, sleep and reduced cortisol. In children, the only placebo-controlled trial of root extract (ages 6 to 12) examined cognition and sleep. No trial has studied adolescents, whose growth, maturation and training load may alter responses, so adult findings cannot be assumed to apply.
An independent collaborator outside the research team will generate the allocation (block size four, stratified by sex and age band, 11 to 15 and 16 to 19) and label bottles with participant codes only. Participants, caregivers and investigators will remain blind until the dataset is locked, and blinding success will be assessed at follow-up. Players aged 11 to 15 take part with parental consent and their own assent, and players aged 16 to 19 consent for themselves. A study medical official will screen medical eligibility. Caregivers or participants will be contacted weekly regarding adverse events, and any suspected supplement-related event will lead to discontinuation and medical review within 24 hours.
Data will be analysed by linear mixed methods. Two investigators will analyse the coded data independently and blind to allocation. Results will be interpreted as short-term responses and will not establish long-term safety or efficacy.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- 適用できない
連絡先と場所
研究連絡先
研究連絡先
- 名前:Alex Levington, PhD(c)
- 電話番号:07882461098
- メール:alex@strengthandnutrition.co.uk
研究連絡先のバックアップ
- 名前:Olivia C Coope, PhD(c)
- メール:occ@spartaresearch.org
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Aged 11 to 19 years on the day of baseline testing
- Male or female player registered with a participating grassroots football club or community football programme, taking part in organised football training at least once a week (any playing ability)
- Able to attend both testing sessions and able to swallow a capsule
- Valid written consent: parent/caregiver consent and player assent (ages 11 to 17), or the player's own consent (ages 18 to 19)
Exclusion Criteria:
- Diagnosed liver, kidney or thyroid condition
- Autoimmune condition (e.g. type 1 diabetes, lupus, rheumatoid or juvenile idiopathic arthritis, inflammatory bowel disease)
- Diabetes or another condition affecting blood sugar; high or low blood pressure requiring treatment
- Regularly taking prescribed medication
- Known allergy or intolerance to ashwagandha, nightshade family plants, corn (maize) or the capsule shell
- Pregnant, possibly pregnant or breastfeeding
- Stomach ulcer; heart condition; chest pain, fainting or seizures during exercise; or medical advice not to do hard exercise
- Current illness or injury that prevents maximal effort
- Surgery planned during the study or within 2 weeks after it, or hospital admission in the last 3 months
- Currently taking, or taken in the past 4 weeks, ashwagandha in any form, including combination products
- Unwilling to avoid starting any new supplement during the six weeks
- Taking part in another research study involving a supplement or medicine in the past 3 months
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:基礎科学
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:トリプル
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Root extract Ashwagandha
450mg of KSM-66 Ashwagandha |
One 450 mg capsule of KSM-66 ashwagandha, taken once daily with a meal for six weeks (42 days). KSM-66 is a full-spectrum extract made from root only, with no leaf, standardised to 5% withanolides (HPLC verified), and supplied with a certificate of analysis for each batch. Capsules are supplied in labelled bottles of 42 and are identical in appearance to the placebo.
他の名前:
|
|
プラセボコンパレーター:Placebo
450mg corn starch |
One 450 mg capsule of corn starch, taken once daily with a meal for six weeks (42 days). The capsule shell, appearance, bottle and labelling are identical to the active capsule. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Salivary cortisol
時間枠:Baseline (week 0) and after six weeks of supplementation
|
Saliva collected with Salivette tubes after an evening training session and analysed by an external laboratory. Reported as the change from baseline to follow-up. |
Baseline (week 0) and after six weeks of supplementation
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Salivary alpha-amylase
時間枠:Baseline (week 0) and after six weeks of supplementation
|
Measured from the same saliva samples as cortisol. |
Baseline (week 0) and after six weeks of supplementation
|
|
Handgrip Strength
時間枠:Baseline (week 0) and after six weeks of supplementation
|
Maximal handgrip strength measured with a CAMRY handgrip dynamometer. |
Baseline (week 0) and after six weeks of supplementation
|
|
Number of participants with adverse events
時間枠:Baseline (week 0) and after six weeks of supplementation
|
Any adverse events reported in the duration of the clinical trial |
Baseline (week 0) and after six weeks of supplementation
|
|
Change in perceived recovery, measured by the Hooper Index
時間枠:Baseline (week 0) and after six weeks of supplementation
|
Self-reported fatigue, stress, sleep quality and muscle soreness on the Hooper Index questionnaire. Individual items are scored 1 (very, very good) to 10 (very, very bad) and the total score is 4 to 40, higher scores indicating poorer recovery. |
Baseline (week 0) and after six weeks of supplementation
|
|
Change in 1 km time-trial performance
時間枠:Baseline (week 0) and after six weeks of supplementation
|
Time taken to complete a 1 km run, as a measure of aerobic fitness and high-intensity running capacity. |
Baseline (week 0) and after six weeks of supplementation
|
協力者と研究者
スポンサー
スポンサー
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- ASH-ADOL-001
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Individual participant data will not be shared. Participants will be minors recruited from a small number of local football clubs, so a dataset of this size (about 50 to 60 players) combined with age, sex and test results could allow re-identification even after coding. Consent and assent were obtained for use of the data within this study only, and the participant code key and contact details will be permanently deleted on 31 May 2027. The fully anonymised dataset will be held securely by the research team and used only for the analyses and publications described in the ethics-approved protocol. Summary results will be reported in the results section of this record and in peer-reviewed publication, with participating clubs not named.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。